The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02977117|
Recruitment Status : Completed
First Posted : November 30, 2016
Last Update Posted : June 6, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Endstage Renal Disease||Other: Dialysate magnesium (1.0 mmol/L) Other: Dialysate magnesium (0.5 mmol/L)||Phase 2|
Patients with end-stage renal disease (ESRD) have a 20-fold increased risk of cardiovascular mortality compared to the general population. Arterial stiffness, likely due to vascular calcification (VC), has been shown to predict cardiovascular mortality in ESRD. Serum calcification propensity (T50) is a novel biomarker, which is believed to reflect the propensity toward ectopic calcification (e.g. VC). Increasing serum magnesium (sMg) should increase T50, which might in turn reduce the formation of VC in patients with ESRD. A cheap and easy way of achieving this would be to increase the concentration of Mg in the dialysate (dMg) of patients with ESRD treated with haemodialysis (HD).
The investigators wish to conduct a randomised controlled double-blind clinical trial to examine whether increasing dMg will improve T50 in subjects with ESRD treated with HD.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||59 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial|
|Study Start Date :||December 2016|
|Actual Primary Completion Date :||June 2017|
|Actual Study Completion Date :||June 2017|
Experimental: Dialysate magnesium 1.0 mmol/L
Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
Other: Dialysate magnesium (1.0 mmol/L)
Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
Active Comparator: Dialysate magnesium 0.5 mmol/L
Maintain dialysate magnesium at 0.5 mmol/L.
Other: Dialysate magnesium (0.5 mmol/L)
Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
- Between-group difference in serum calcification propensity at follow-up [ Time Frame: 4 weeks ]
- Within-group change in serum calcification propensity [ Time Frame: 2 weeks ]
- Within-group change and between-group difference in serum magnesium [ Time Frame: 4 weeks ]
- Change in serum magnesium after intervention [ Time Frame: 2 weeks ]
- Within-group change and between-group difference in serum parathyroid hormone [ Time Frame: 4 weeks ]
- Change in serum parathyroid hormone after intervention [ Time Frame: 2 weeks ]
- Change in fibroblast growth factor 23 during intervention [ Time Frame: 4 weeks ]
- Incidence of intradialytic hypotension during intervention [ Time Frame: 4 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age ≥ 18 years.
- Treatment with maintenance haemodialysis for more than 3 months.
- Dialysate magnesium of 0.5 mmol/L (standard concentration).
- Serum magnesium < 1.2 mmol/L on average of previous measurements within the last 3 months.
- Women of childbearing age must be actively using contraceptive therapy (p-pills, estrogen depots or intrauterine device) as well as have a negative pregnancy test.
- Written informed consent.
- Treatment with peritoneal dialysis.
- Parathyroid hormone > 66 ρmol/L.
- Previous parathyroidectomy.
- Current treatment with magnesium containing medication or supplements.
- Other diseases or conditions, which, in the opinion of the site investigator, would prevent participation in or completion of the trial.
- Pregnancy or breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02977117
|Hillerod, Denmark, 3400|
|Responsible Party:||Iain Bressendorff, MD, Nordsjaellands Hospital|
|Other Study ID Numbers:||
|First Posted:||November 30, 2016 Key Record Dates|
|Last Update Posted:||June 6, 2018|
|Last Verified:||June 2018|
chronic kidney disease - mineral and bone disorder
serum calcification propensity
Kidney Failure, Chronic
Calcium Metabolism Disorders
Renal Insufficiency, Chronic